Project Grant K23HL183818
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University a $195,846 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for April 30, 2030. This K23 mentored career development award funds a prospective cohort study investigating the role of blood-brain barrier (BBB) disruption in ischemic brain injury and cognitive impairment among patients with sickle cell...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $232,836 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective December 1, 2025 through November 30, 2027. This award supports quantitative neuroimaging research to develop biomarkers of ischemic risk in adults with sickle cell disease (SCD). The research employs non-invasive advanced imaging methods, including arterial spin...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Illinois a $755,853 Project Grant effective September 15, 2025, through June 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds research investigating sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a therapeutic intervention for sickle cell disease (SCD)-related chronic kidney disease (CKD). The research will leverage preliminary data...
- Federal Project Grant Award Summary Drexel University received a $503,870 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2029. The award supports fundamental research on anti-sickling therapies for sickle cell disease, which affects approximately 100,000 Americans. The project addresses critical knowledge gaps in understanding how fetal hemoglobin...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a $765,931 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 22, 2025, through July 31, 2030, to conduct a multi-center hybrid effectiveness-implementation trial evaluating patient-facing, evidence-based guidelines for sickle cell disease (SCD) management delivered through a mobile health (mHealth) application plus printed booklets. The primary...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a $769,994 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the impact of left ventricular assist device (LVAD) implantation on cerebral hemodynamics and cognitive function. The research project, which commenced on September 5, 2025, and is scheduled for completion by July 31, 2029, will utilize transcranial Doppler...
- Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $277,500 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of July 31, 2027. The project addresses executive functioning impairment in pediatric patients with sickle cell disease (SCD) through a clinical investigation of methylphenidate (MPH) efficacy and safety. Sickle cell...
- Federal Project Grant Summary The University of Cincinnati's Sponsored Research Services Division received a $654,628 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective March 6, 2026, through February 28, 2031. This research initiative investigates the relationship between peripheral blood proteomics and cognitive decline following...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of North Carolina at Chapel Hill a Project Grant totaling $761,028 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multi-site prospective study examining sleep-associated hypoxemia in adults with sickle cell anemia (SCA). The four-year study, active from September 15, 2025 through June 30, 2029, investigates the prevalence, clinical impact, and therapeutic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Johns Hopkins University a Project Grant totaling $1,352,049 on May 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microglial glutaminase in HIV-induced sleep deficits. The research addresses a significant health burden affecting 50–70% of virologically suppressed people with HIV (VSPWH), who experience insomnia rates 2.5 times higher than the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Cincinnati a Project Grant totaling $186,613 (obligated April 10, 2026) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a five-year neuroimaging research study extending through March 31, 2031. The research deliverables include the measurement and mapping of activated microglia density and distribution in the brains of 45 individuals with sickle cell disease (SCD) compared to 15 healthy controls using advanced diffusion magnetic resonance imaging (dMRI) technology. The study will establish correlations between microglial activation patterns—particularly in the hippocampus and frontal lobes—and cognitive deficits as assessed through the National Institutes of Health Toolbox Cognition Battery, with an exploratory analysis quantifying systemic inflammatory and neurodegeneration biomarkers. The project addresses a critical clinical need by developing neuroimaging biomarkers to detect and monitor neuroinflammation in adults with SCD, a progressive neurodegenerative condition associated with significant cognitive impairment. The research outcomes will provide evidence-based methodologies for assessing microglial activation as a mechanistic contributor to cognitive deficits in SCD populations and establish foundational data for evaluating therapeutic intervention responses, with potential applications extending to other neurodegenerative disorders characterized by similar neuroinflammatory pathways.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $186.6k | 4/8/26 |